Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical safety assessment of JNJ-10450232 (NTM-006), a structural analog of acetaminophen, that does not cause hepatotoxicity at supratherapeutic doses.
Zhou J, De Jonghe S, Codd EE, Weiner S, Gallacher D, Stahle P, Kelley MF, Kuffner EK, Flores CM, Eichenbaum GE. Zhou J, et al. Among authors: codd ee. Regul Toxicol Pharmacol. 2023 Jan 4:105334. doi: 10.1016/j.yrtph.2023.105334. Online ahead of print. Regul Toxicol Pharmacol. 2023. PMID: 36608923 Free article.
Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study.
Bach T, Galbiati S, Kennedy JK, Deye G, Nomicos EYH, Codd EE, Garcia HH, Horton J, Gilman RH, Gonzalez AE, Winokur P, An G. Bach T, et al. Among authors: codd ee. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01018-20. doi: 10.1128/AAC.01018-20. Print 2020 Oct 20. Antimicrob Agents Chemother. 2020. PMID: 32816721 Free PMC article. Clinical Trial.
Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study.
An G, Murry DJ, Gajurel K, Bach T, Deye G, Stebounova LV, Codd EE, Horton J, Gonzalez AE, Garcia HH, Ince D, Hodgson-Zingman D, Nomicos EYH, Conrad T, Kennedy J, Jones W, Gilman RH, Winokur P. An G, et al. Among authors: codd ee. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02255-18. doi: 10.1128/AAC.02255-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30745383 Free PMC article. Clinical Trial.
Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadine.
Codd EE, Baker J, Brandt MR, Bryant S, Cai C, Carson JR, Chevalier KM, Colburn RW, Coogan TP, Dax SL, Decorte B, Kemmerer M, Legrand EK, Lenhard JM, Leone AM, Lin L, Mabus JR, McDonnell ME, McMillian MK, McNally JJ, Stone DJ Jr, Wang CY, Zhang SP, Flores CM. Codd EE, et al. Toxicol Sci. 2010 Oct;117(2):493-504. doi: 10.1093/toxsci/kfq200. Epub 2010 Jul 8. Toxicol Sci. 2010. PMID: 20616206
JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence.
Codd EE, Carson JR, Colburn RW, Stone DJ, Van Besien CR, Zhang SP, Wade PR, Gallantine EL, Meert TF, Molino L, Pullan S, Razler CM, Dax SL, Flores CM. Codd EE, et al. J Pharmacol Exp Ther. 2009 Apr;329(1):241-51. doi: 10.1124/jpet.108.146969. Epub 2009 Jan 16. J Pharmacol Exp Ther. 2009. PMID: 19151246
72 results